source
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
- J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth PotentialJohn Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…